Low-flow mediated constriction incorporated indices as indicators of cardiovascular risk in smokers.

N. Norioka,Y. Takemoto,Masanori Kobayashi,Ayako Makuuchi,J. Yoshikawa,Yoichi Yamazaki,Y. Kamiyama,T. Shuto,M. Yoshiyama

DOI: https://doi.org/10.1016/j.atherosclerosis.2016.06.022

IF: 5.3

2016-08-01

Atherosclerosis

Abstract:

What problem does this paper attempt to address?

Wireless wideband SAW sensor - antenna design

M. Gallagher,B. Santos,D. Malocha

DOI: https://doi.org/10.1109/FREQ.2010.5556326

2010-06-01

Abstract:Wireless SAW RFID sensors offer several advantages over similar silicon technology that include passive operation, radiation hardness, and the ability to operate in extreme temperatures. Due to these unique material and device properties, NASA has shown considerable interest in passive, wireless SAW sensors for ground and space flight operations. Several embodiments of SAW sensors have been well established in literature, but often the limiting factor on device size and performance is the tag antenna. Therefore, in order to develop a unified sensor target, a discussion of design principles and tradeoffs for both the SAW device and antenna will be presented in this paper. Antennas designed and fabricated will be presented, including a simple disk monopole, a planar open-sleeve dipole, and an on-wafer meandered dipole, with a discussion on gain, size, and bandwidth. The evolution of the antenna design is toward smaller antennas that minimize tradeoffs. The eventual wafer level integration of the antenna allows the sensor application to exploit some of the known SAW substrate advantages and has application in high temperature or strain sensors. Example orthogonal frequency coded (OFC) temperature sensors on YZ-LiNbO3 for use at 250 and 915MHz will be used as device examples. By properly designing the combined antenna/SAW target matching, insertion loss can be minimized and range increased. Experimental results on the integration of several sensor targets will be presented. Work presented is a foundation for a realizable wireless, multi-sensor platform.
Hepatitis B immune globulin (HBIG): efficacy in the interruption of vertical transmission of hepatitis B virus (HBV) carrier state.

D. Pongpipat,V. Suvatte,A. Assateerawatts

Journal of the Medical Association of Thailand = Chotmaihet thangphaet

Abstract:
Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis Post-hoc analysis of a multicentre, prospective, real-world study

Wenting Sun,Keqin Hua,Li Hong,Juxin Zhang,Min Hao,Jianliu Wang,Jun Zhang,Valerie Perrot,Hongbo Li,Xinmei Zhang

DOI: https://doi.org/10.1097/MD.0000000000026753

IF: 1.6

2021-01-01

Medicine

Abstract:Triptorelin has been used after surgery in deep infiltrating endometriosis. This post-hoc analysis aimed to evaluate symptom control between patients receiving 1-3 triptorelin injections and those receiving 4-6 injections within 24 months of conservative surgery for deep infiltrating endometriosis, in the real-world. Included patients were divided into two groups (received up to 3 months injections in group A, 4-6 injections in group B) based on the numbers of triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) administration. Evolution in score of pain intensity at 3, 6, 9, 12, 18, and 24 months after primary triptorelin administration and symptom improvement/recurrence rates between two groups were compared. Symptoms of pain intensity were assessed using a visual analogue scale (VAS) with a range from 0 to 10 cm. An improvement in symptoms was defined as a reduction of at least 3 cm or 3 units from pre-surgery levels. 156 patients in group A and 228 in group B. Pain symptom score (mean +/- standard deviation) diminished to a nadir at 3-months for group A and 6-months for group B; at 6-months nadir scores were significantly lower in group B (0.9 +/- 1.7 vs 0.4 +/- 1.2 respectively, P = .002). No significant difference for pain symptom scores between both groups at 24-months (P = .269). The 6-month and 24-month cumulative improvement rates of pain (80.6% vs 89.8%, P = .014 and 82.6% vs 90.7%, P = .025) and gastro-intestinal symptoms (61.0% vs 80.8%, P = .022 and 61.0% vs 83.3%, P = .008) were significantly higher in group B, whereas there was no significant difference in rates of menstrual disorders and urinary symptoms. There is no significant difference for 12-months and 24-months cumulative recurrence rates of total symptoms between both groups (11.3% vs 13.8%, P = .568 and 16.1% vs 26.0%, P = .094). In women with deep infiltrating endometriosis, longer treatment with triptorelin following conservative surgery was associated with a decrease in symptom intensity and greater improvement of pain symptoms in the short-term and greater improvement of gastro-intestinal symptoms in the long-term. Trial registration number: ClinicalTrials.gov, NCT01942369.
Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties.

R. Taguchi,Koki Hatayama,Tomohito Takahashi,Takafumi Hayashi,Yuki Sato,D. Sato,K. Ohta,H. Nakano,Chigusa Seki,Y. Endo,K. Tokuraku,K. Uwai

DOI: https://doi.org/10.1016/j.ejmech.2017.07.026

IF: 7.088

2017-09-29

European Journal of Medicinal Chemistry

Abstract:
Letrozole Combined With Oral Contraceptives Versus Oral Contraceptives Alone In The Treatment Of Endometriosis-Related Pain Symptoms: A Pilot Study

Yi Zhao,Xiaofei Luan,Yuya Wang

DOI: https://doi.org/10.1080/09513590.2020.1807502

2021-01-01

Gynecological Endocrinology

Abstract:Background: To compare the efficacy and the tolerability of letrozole combined with oral contraceptives versus oral contraceptives alone in treating endometriosis-related pain.Methods: A total of 820 women with endometriosis presented with endometriosis-related pain were enrolled with this study. Patients were randomly treated either with letrozole (2.5 mg/day) combined with oral contraceptives (Desogestrel and Ethinylestradiol Tablets)or oral contraceptives (Desogestrel and Ethinylestradiol Tablets) alone for 6 months. Changes in pain symptoms during treatment and in 1 months after treatment, 6-month follow-up and 12-month follow-up were evaluated. Adverse effects of each treatment protocol were recorded.Results: At completion of treatment, the intensity of chronic pelvic pain continued to decrease during treatment and at 1-month after treatment it was significantly lower than at 6-month follow-up and baseline level both in LE + oral contraceptives group (Mean +/- SD,1.5 +/- 1.4) and in oral contraceptives alone group(Mean +/- SD,2.9 +/- 1.2).The intensity of chronic pelvic pain and deep dyspareunia was significantly decrease at both 1-month after treatment and 6-month follow-up.Conclusions: This treatment for endometriosis is a promising new modality that warrants further investigation.
Investigation of the 12-Month Efficacy and Safety of Low-Dose Mifepristone in the Treatment of Painful Adenomyosis

Shu-Yi Chen,Meng-Dan Zhao,Wen-Ting Sun,Li-Bo Zhu,Xin-Mei Zhang

DOI: https://doi.org/10.1097/rd9.0000000000000031

2022-01-01

Reproductive and Developmental Medicine

Abstract:Objective::To study the 12-month effects and possible mechanisms of low-dose mifepristone in the treatment of adenomyosis.Methods::Patients included in this retrospective study had painful adenomyosis and previously received 5 mg mifepristone daily (group A, n = 45) or 5 mg mifepristone daily with a poor-effect levonorgestrel-releasing intrauterine device (group B, n = 13) for 12 months. Uterine size, serum CA125 levels, estradiol levels, Visual Analogue Scale (VAS) score, endometrial thickness, and hemoglobin levels were compared before and after treatment and investigated again at 3 to 6 months after drug withdrawal. Another 8 patients with adenomyosis (group C, n = 8) who underwent surgery for severe dysmenorrhea during the same period were only used as a control group for immunohistochemical research. Endometrial biopsy results and expression of nerve growth factor (NGF), cyclooxygenase-2 (COX-2), and nuclear-associated antigen Ki-67 (Ki-67) in endometrial tissues and adenomyotic lesions were also analyzed. Results::The VAS scores in both experimental groups at all time points during treatment and follow-up were significantly lower ( P <0.001) than those before treatment. The uterine size was significantly reduced, and endometrial thickness was distinctly thicker after 12 months of treatment than that before treatment in group A receiving 5 mg/d mifepristone. The immunohistochemical expression of NGF and COX-2 decreased in both eutopic and ectopic endometrium after treatment, whereas that of Ki-67 slightly increased in eutopic endometrium after treatment and rapidly recovered to the baseline value after stopping mifepristone. There were no signs of hyperplasia, atypical hyperplasia, or malignancy in the endometrial biopsies. Conclusions::The results suggested that a daily dose of 5 mg mifepristone for 12 months down-regulated the expression of NGF and COX-2 and was effective in treating painful adenomyosis with few side effects.
The efficacy and safety of up to 24 weeks of triptorelin therapy following conservative surgery in patients with deep infiltrating endometriosis (DIE): a multicentre, prospective, non-interventional study in China

Li bo Zhu,Zheng Guan,Yan Huang,Keqin Hua,Liguo Ma,Jian Zhang,Dazhen Yang,Valerie Perrot,Hongbo Li,Xinmei Zhang

DOI: https://doi.org/10.22541/au.158981325.53850315

2020-01-01

Abstract:OBJECTIVE: To evaluate the efficacy and safety of up to 24 weeks of triptorelin treatment after conservative surgery for deep infiltrating endometriosis (DIE). DESIGN: Multicentre, prospective, non-interventional. SETTING: 18 tertiary hospitals in China. POPULATION: Premenopausal women aged ≥ 18 years treated with triptorelin 3.75 mg once every 28 days for up to 24 weeks after conservative surgery for DIE METHODS: Endometriosis symptoms were assessed, using a visual analogue scale (0–10 cm) or numerical range (0–10), at baseline (pre-surgery) and routine visits 3, 6, 9, 12, 18 and 24 months after surgery. MAIN OUTCOME MEASURES: Change in symptom intensity over time. RESULTS: A total of 384 women were analysed (mean [SD] age, 33.4 [6.2] years). Scores for all symptoms assessed (pelvic pain, dysmenorrhoea, ovulation pain, dyspareunia, menorrhagia, metrorrhagia and gastrointestinal and urinary symptoms) decreased from baseline over 24 months. Cumulative improvement rates in pelvic pain, dysmenorrhoea, ovulation pain and dyspareunia were 74.4%, 83.6%, 55.1% and 66.9%, respectively. The 24-month cumulative recurrence rate (≥ 1 symptom) was 22.2%. The risk of symptom recurrence was higher in patients with ≥ 2 versus 1 lesion (odds ratio [OR] 2.539; 95% CI: 1.458–4.423; p = 0.001) and patients with moderate (OR 5.733; 95% CI: 1.623–20.248; p = 0.007) or severe (OR 8.259; 95% CI: 2.449–27.851; p = 0.001) pain versus none/mild pain. Triptorelin was well tolerated. CONCLUSIONS: Triptorelin after conservative surgery for DIE improved symptoms over 24 months of follow up. FUNDING: Sponsored by Ipsen
The Efficacy and Safety of Triptorelin-Therapy Following Conservative Surgery for Deep Infiltrating Endometriosis A Multicenter, Prospective, Non-Interventional Study in China

Libo Zhu,Zheng Guan,Yan Huang,Keqin Hua,Liguo Ma,Jian Zhang,Dazhen Yang,Valerie Perrot,Hongbo Li,Xinmei Zhang

DOI: https://doi.org/10.1097/md.0000000000028766

IF: 1.6

2022-01-01

Medicine

Abstract:Triptorelin is one of the most commonly used gonadotropin-releasing hormone agonists and has been used in the treatment of deep infiltrating endometriosis (DIE). This study aimed to evaluate the efficacy and safety of up to 24 weeks of triptorelin treatment after conservative surgery for DIE. This prospective, non-interventional study was performed in 18 tertiary hospitals in China. Premenopausal women aged >= 18 years treated with triptorelin 3.75 mg once every 28 days for up to 24 weeks after conservative surgery for DIE were included. Endometriosis symptoms were assessed, using a visual analogue scale (0-10 cm) or numerical range (0-10), at baseline (pre-surgery) and routine visits 3, 6, 9, 12, 18, and 24 months after surgery. Changes in symptom intensity over time were primary outcome measures. A total of 384 women (mean [standard deviation] age, 33.4 [6.2] years) were analyzed. Scores for all symptoms (pelvic pain, dysmenorrhea, ovulation pain, dyspareunia, menorrhagia, metrorrhagia, and gastrointestinal and urinary symptoms) assessed decreased from baseline over 24 months. Cumulative improvement rates in pelvic pain, dysmenorrhoa, ovulation pain, and dyspareunia were 74.4%, 83.6%, 55.1%, and 66.9%, respectively. The 24-month cumulative recurrence rate (>= 1 symptom) was 22.2%. The risk of symptom recurrence was higher in patients with >= 2 versus 1 lesion (odds ratio [OR] 2.539; 95% CI: 1.458-4.423; P = .001) and patients with moderate (OR 5.733; 95% CI: 1.623-20.248; P = .007) or severe (OR 8.259; 95% CI: 2.449-27.851; P = .001) pain versus none/mild pain. Triptorelin was well tolerated without serious adverse events. Triptorelin after conservative surgery for DIE improved symptoms over 24 months of follow up. The recurrence rate of symptoms was low and triptorelin was generally well tolerated. Trial registration number: ClinicalTrials.gov, NCT01942369.
Beta3-adrenoceptor is involved in the inhibition of small intestinal motility due to restraint stress in rats.

F. Tsukada,M. Sugawara,K. Sawamura,Y. Ohuchi,H. Kohno,Y. Ohkubo

DOI: https://doi.org/10.1248/BPB.24.995

2001-09-01

Biological and Pharmaceutical Bulletin

Abstract:We have reported that acute restraint stress inhibits small intestinal motility in rats. In order to clarify this inhibitory mechanism, we examined the effects of alpha- and beta-adrenergic antagonists on the inhibition of small intestinal motility induced by restraint stress. This inhibition underwent recovery by propranolol (beta1/beta2-antagonist) or SR59230A (beta3-antagonist), but not by atenolol (beta1-antagonist), ICI-118,551 (beta2-antagonist), prazosin (alpha1-antagonist) or yohimbine (alpha2-antagonist). These results suggest that beta3-adrenoceptors play an important role in the inhibition of small intestinal motility caused by restraint stress.
Electronic structure of the neutral manganese acceptor in gallium arsenide.

Schneider,Kaufmann,Wilkening,Baeumler,Köhl

DOI: https://doi.org/10.1103/PHYSREVLETT.59.240

IF: 8.6

1987-07-13

Physical Review Letters

Abstract:A new maganese-related isotropic electron-spin-resonance signal at g=2.77 has been observed in GaAs. It is shown to arise from the neutral Mn acceptor, ${\mathrm{Mn}}^{0}$. The analysis gives an answer to the longstanding question of whether the structure of ${\mathrm{Mn}}^{0}$ correponds to the 3${\mathrm{d}}^{4}$ or to the 3${\mathrm{d}}^{5}$+hole. The data clearly favor the latter case, thus revealing that Mn is an exception within the 3d acceptor family in GaAs.
Does Nomegestrol Acetate Plus 17β-Estradiol Oral Contraceptive Improve Endometriosis-Associated Chronic Pelvic Pain in Women?

Salvatore Caruso,Antonio Cianci,Marco Iraci,Valentina Fava,Salvatore Di Pasqua,Stefano Cianci

DOI: https://doi.org/10.1089/jwh.2020.8291

2020-09-01

Abstract:Background: To evaluate the effects of a 24/4 regimen combined oral contraceptive (COC) containing 1.5 mg 17β-estradiol (E2) and 2.5 mg nomegestrol acetate (NOMAC) compared to on-demand nonsteroidal anti-inflammatory drugs (NSAIDs) on women affected by endometriosis-associated chronic pelvic pain (the primary end point) and their quality of life (QoL) and sexual function (the secondary end points).Materials and Methods: Ninety-nine women on E2/NOMAC constituted the study group; and 63 women on NSAIDs constituted the control group. The visual analogic scale was used to measure the levels of pelvic pain, dysmenorrhea, and dyspareunia. To assess their QoL, sexual function, and sexual distress, the Short Form-36 (SF-36), the Female Sexual Function Index (FSFI), and the Female Sexual Distress Scale (FSDS) were used, respectively. The study included two follow-ups at 3 and 6 months.Results: Improvement in chronic pelvic pain was observed in the study group at both the 3- and 6-month follow-ups (p < 0.001). SF-36, FSFI, and FSDS had a similar trend at the 3- and 6-month follow-ups (p < 0.001). Women on NSAIDs did not report any reduction in pain symptoms or improvement in QoL (p ≤ 0.4). However, they had a limited improvement of their FSFI and FSDS (p < 0.001). The improvement of the pain symptoms, QoL, FSFI, and FSDS, was more evident in women on E2/NOMAC than in those on NSAIDs, when the study group and control group values were compared at the 3- and 6-month follow-ups (p < 0.001).Conclusions: Women on E2/NOMAC COC showed a better reduction of endometriosis-associated chronic pelvic pain and an improvement of their QoL and sexual activity than those of the women on NSAIDs.
A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women

Zheng Li,Hong Yuan Zhang,Ying Jun Zhu,Yuan Jing Hu,Peng Peng Qu

DOI: https://doi.org/10.1016/j.ejogrb.2014.10.022

Abstract:Objectives: Different gonadotropin-releasing-hormone agonist (GnRH-a) formulations with different potency and associated side effects, therefore, different compliance and persistence of therapy. This study was to evaluate the difference of hormonal profile and side effects due to hypoestrogenic status after treatment of leuprorelin and triptorelin in Chinese women with ovarian endometrioma after conservative surgical treatment. Study design: A total of 302 women underwent laparoscopic excision of ovarian endometriomas with rASRM III and IV were enrolled in the study.Subjects were randomized into two groups with use of a random table. Twenty two patients dropped out during the study. Thus 142 patients had three doses of i.m. leuprorelin (group A) and 138 patients had three doses of i.m. triptorelin(group B) at 4 weeks intervals after surgical treatment. Menopausal symptoms were evalutaed using a questionnaire and serum sex hormonal levels were also measured during the follow-up. Results: At week 4 after the treatment, most of the patients in leuprorelin group have no obvious side effects. After 9 weeks, bone pain, hot flashes and sweating, and irregular bleeding were the main side effects and showed no difference between the groups. Anxiety, depression, vaginal dryness, headache, and acne rates were all significantly higher in triptorelin group than in leuprorelin group. A significant difference in FSH (p=0.003), LH (p=0.026) and E2 (p=0.002) levels between the groups were observed after 21 days of the GnRHa treatment. The FSH (p=0.021) and E2 (p=0.033) levels remained higher in the leuprorelin group than the triptorelin group after six weeks of treatment, but the difference of LH(p=0.917) level was no longer discernible. Conclusion: Leuprorelin in down-regulating the pituitary-ovarian function was more moderate, and the hormonal levels decrease progressively and gradually, therefore, with lower rate of menopausal symptoms. Leuprorelin acetate maybe better tolerated than triptorelin.
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

Hannah A. Blair

DOI: https://doi.org/10.1007/s40265-024-02018-3

2024-04-10

Drugs

Abstract:An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree ® (USA); Ryeqo ® (EU)] (hereafter referred to as relugolix combination therapy) has been approved in the USA for the management of moderate to severe pain associated with endometriosis in premenopausal women and in the EU for the symptomatic treatment of endometriosis in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis. The gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix decreases estradiol and progesterone levels, while the addition of estradiol/norethisterone acetate mitigates hypoestrogenic effects including bone mineral density (BMD) loss and vasomotor symptoms. In two pivotal phase III trials, relugolix combination therapy significantly improved dysmenorrhoea and non-menstrual pelvic pain in premenopausal women with moderate to severe endometriosis. The combination also reduced overall pelvic pain and dyspareunia, reduced analgesic and opioid use, and improved health-related quality of life. The efficacy of relugolix combination therapy was sustained over the longer term (up to 2 years). Relugolix combination therapy was generally well tolerated and BMD loss over time was minimal. With the convenience of a once daily oral dosing regimen, relugolix combination therapy is a valuable addition to the options currently available for the management of endometriosis-associated pain.

pharmacology & pharmacy,toxicology
Long acting progestogens versus combined oral contraceptive pill for preventing recurrence of endometriosis related pain: the PRE-EMPT pragmatic, parallel group, open label, randomised controlled trial

Kevin G Cooper,Siladitya Bhattacharya,Jane P Daniels,Andrew W Horne,T Justin Clark,Ertan Saridogan,Versha Cheed,Danielle Pirie,Melyda Melyda,Mark Monahan,Tracy E Roberts,Emma Cox,Clive Stubbs,Lee J Middleton

DOI: https://doi.org/10.1136/bmj-2023-079006

2024-05-16

BMJ

Abstract:ObjectivesTo evaluate the clinical effectiveness of long acting progestogens compared with the combined oral contraceptive pill in preventing recurrence of endometriosis related pain.DesignThe PRE-EMPT (preventing recurrence of endometriosis) pragmatic, parallel group, open label, randomised controlled trial.Setting34 UK hospitals.Participants405 women of reproductive age undergoing conservative surgery for endometriosis.InterventionsParticipants were randomised in a 1:1 ratio using a secure internet facility to a long acting progestogen (depot medroxyprogesterone acetate or levonorgestrel releasing intrauterine system) or the combined oral contraceptive pill.Main outcome measuresThe primary outcome was pain measured three years after randomisation using the pain domain of the Endometriosis Health Profile 30 (EHP-30) questionnaire. Secondary outcomes (evaluated at six months, one, two, and three years) included the four core and six modular domains of the EHP-30, and treatment failure (further therapeutic surgery or second line medical treatment).Results405 women were randomised to receive a long acting progestogen (n=205) or combined oral contraceptive pill (n=200). At three years, there was no difference in pain scores between the groups (adjusted mean difference −0.8, 95% confidence interval −5.7 to 4.2, P=0.76), which had improved by around 40% in both groups compared with preoperative values (an average of 24 and 23 points for long acting progestogen and combined oral contraceptive pill groups, respectively). Most of the other domains of the EHP-30 also showed improvement at all time points compared with preoperative scores, without evidence of any differences between groups. Women randomised to a long acting progestogen underwent fewer surgical procedures or second line treatments compared with those randomised to the combined oral contraceptive pill group (73 v 97; hazard ratio 0.67, 95% confidence interval 0.44 to 1.00).ConclusionsPostoperative prescription of a long acting progestogen or the combined oral contraceptive pill results in similar levels of improvement in endometriosis related pain at three years, with both groups showing around a 40% improvement compared with preoperative levels. While women can be reassured that both options are effective, the reduced risk of repeat surgery for endometriosis and hysterectomy might make long acting reversible progestogens preferable for some.Trial registrationISRCTN registry ISRCTN97865475.

medicine, general & internal
Our surgical heritage: the role of the Department of Paediatric Surgery in the development of paediatric surgery in Cape Town, in Africa, and around the world.

H. Rode,A. Millar

DOI: https://doi.org/10.7196/SAMJ.5744

2012-03-23

Abstract:The Department of Paediatric Surgery at the University of Cape Town has made a remarkable contribution to the academic body of knowledge of Paediatric Surgery both in South Africa and around the world. It has played a key role in the development of the specialty in South Africa and through the South African diaspora has trained many paediatric surgeons who have made their mark internationally. More recently it has become a major focus of teaching and training for African paediatric surgeons. This article traces this legacy through its origins in the early 1920s to its current prominent position in the world paediatric surgical community.
Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents

Essam Othman,Ayman Al-Hendy,Radwa Mostafa,Cornelis Lambalk,Velja Mijatovic

DOI: https://doi.org/10.2147/ijwh.s442357

2024-02-28

International Journal of Women s Health

Abstract:Essam R Othman, 1, 2 Ayman Al-Hendy, 3 Radwa Mostafa, 1 Cornelis B Lambalk, 2 Velja Mijatovic 2 1 OB-GYN Department, Assiut University, Assiut, 71515, Egypt; 2 Academic Endometriosis Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; 3 Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, 60637, USA Correspondence: Essam R Othman, Department of Obstetrics and Gynecology, Assiut University, Assiut, Egypt, Email Current medical treatment options for endometriosis associated pains are inadequate. Evidence on effects of nonsteroidal anti-inflammatory drugs is scarce. Around one third of patients are not responsive to oral contraceptives or progestins due to progesterone resistance. Gonadotropin-releasing hormone (GnRH) agonists can only be used for a short duration because of associated side effects. Oral GnRH antagonists, including elagolix, relugolix, and linzagolix allow oral administration, induce dose dependent reduction of estradiol levels, do not cause initial flare up of endometriosis symptoms, and allow the fast return of ovarian function and menstruation after discontinuation. Elagolix at a low dose of 150 mg once daily, or the higher dose of 200 mg twice daily, significantly increased the proportion of women achieving clinically meaningful decline of dysmenorrhea, noncyclic pelvic pain, and dyspareunia. Relugolix at an oral dose of 40 mg/day results in improvement in different forms of endometriosis related pelvic pain, with an efficacy and side effect profile similar to that of GnRH agonists. Adding 1 mg of estradiol and 0.5 mg of norethindrone to 40 mg of relugolix (relugolix combination therapy) allows extension of treatment to 24 weeks with maintained efficacy and an improved side effect profile. Linzagolix, in a dose of 75 mg/day, can be used alone to treat endometriosis associated pain. For severe pelvic pain and dyspareunia, linzagolix can be used in a high dose of 200 mg/day with hormonal add-back therapy to preserve bone health. Plain Language Summary: Oral gonadotropin-releasing hormone (GnRH) antagonists, including elagolix, relugolix, and linzagolix, represent a new addition in the armamentarium against endometriosis associated pain. They are given orally, do not cause an initial flare-up of disease symptoms, allow a return of menses quickly after their withdrawal and produce a balance between ability to relieve endometriosis associated pain and side effects profile. The addition of hormonal agents like estradiol 1 mg and norethindrone acetate 0.5 mg to relugolix (relugolix combination therapy) allowed longer use of the medication for relief of endometriosis associated pain while reducing side effects like bone mineral density loss and hot flushes. Keywords: endometriosis, pain, elagolix, relugolix, linzagolix, estradiol, norethindrone Endometriosis is a chronic inflammatory estrogen dependent disorder that is defined by the presence of endometrial-like tissue outside the uterine cavity. 1 The disease affects 2–10% of women in their reproductive years. 2 Endometriosis is associated with subfertility and debilitating painful symptoms including dysmenorrhea, dyspareunia, dysuria, dyschezia, and chronic pelvic pain. 3 Other associated comorbidities include chronic pain syndromes, fatigability, anxiety/depression, autoimmune diseases, and an increased risk of certain types of cancers. 4 Endometriosis diagnosis is often delayed for 4–11 years after symptoms start. 5 Women with endometriosis have impaired quality of life and lose, on average, 11 working hours per week, mainly due to reduced employability at work. 6 The financial burden of endometriosis approaches 27,855 USD per patient per year, mounting to 22 billion USD at the country level in the United States alone in treatment, productivity loss and health care costs. 7 Symptomatic medical treatment options of endometriosis include analgesia and various hormonal suppression therapies. 8,9 Surgical treatment involves excision of endometriotic lesions to reduce pelvic pain, for recovery of organ dysfunction or to enhance fertility. However, nearly 50% of women undergoing endometriosis surgery may need repeat surgery within 5 years for recurrent symptoms, especially if hormonal treatment is avoided. 10 Assisted reproductive technologies are often used to treat endometriosis related infertility because of the associated tubal dysfunction, diminished ovarian reserve or inability to have sexual intercourse. 11 Although it is traditionally believed that pregnancy has a favorable influence on endometriosis, its negative impact on pregnancy is currently -Abstract Truncated-

obstetrics & gynecology
[Effect of reserpine treatment, in doses "depleting" tissue catecholamines, on myocardial sensitivity to procaine amide].

G. Lorentz,D. Lombardi,R. Gusmano

1967-11-01

Folia Cardiologica

Abstract:
GASTROENTERIC CUTANEOUS FISTULA. TRACT OCCLUSION FOR TREATMENT.

G. L. Jordan

DOI: https://doi.org/10.1001/ARCHSURG.1964.01310220030006

1964-04-01

Archives of Surgery

Abstract:When one encounters an opening through which there is loss of fluid and valuable minerals, the natural inclination is to place a plug into it. Consequently, it is not surprising that some of the earliest attempts to treat gastroenteric fistulas utilized this principle. According to Ochsner, Reyband advocated insertion of wood or ivory plates into the fistulous opening as early as 1827, and in 1842 Kleybolte described two leather discs connected by a thread which were used for this purpose.4During the ensuing 100 years, plugging of the external opening of an enteric fistula was advocated from time to time. The plugs were made of various materials including ordinary gauze packing, wet cotton, iodoform gauze, and substances such as chewing gum which could be readily molded to fit the opening.1,2Some authors have reported the use of equipment made specifically for this purpose. Stone in 1941 described a
Why do estrogens matter: a systematic review and meta-analysis on use of gnrh antagonists, with or without add-back therapy, for endometriosis-associated pain

Manuela Viviano,Giuseppe Benagiano,Sun-Wei Guo,Nicola Pluchino

DOI: https://doi.org/10.1016/j.rbmo.2024.104321

IF: 4.567

2024-06-13

Reproductive BioMedicine Online

Abstract:GnRH antagonists (GnRH-Ants) have been demonstrated to reduce endometriosis-associated pain. As a direct consequence of the hypoestrogenic state they induce, however, when used at higher dosages GnRH-Ants are not recommended for long-term use This unwanted effect may be eliminated by the so-called add-back therapy. This review was conducted to assess the safety and efficacy of GnRH-Ants, with or without add-back hormonal replacement therapy (ABT). Out of the 345 studies selected through the initial search, seven randomized-controlled trials were included, comparing different oral GnRH-ants at varying dosages, from a minimum of 50 mg to a maximum of 200 mg once/twice daily. Women treated with GnRH-Ants at the lowest dose had significantly higher mean pain score reductions from baseline throughout treatment as compared with those treated with placebo (OR=-13.12, 95% CI=(-17.35, -8.89) and (OR= -3.08, 95%CI =(-4.39, -1.76) for dysmenorrhea and non-menstrual pelvic pain, respectively . Compatibly with the dose-response effect, we found a positive correlation between responsive rates and adverse events rates. While GnRH-Ants offer an advantage in terms of pain reduction for endometriosis, the more recent literature suggests the use of GnRH-Ants with ABT which, while mitigating the hypoestrogenic effects of GnRH-Ants, maintain their efficacy, while allowing their long-term use.

obstetrics & gynecology,reproductive biology
Acupuncture and Related Therapies for Endometriosis: A Network Meta-Analysis of Randomized Controlled Trials

Haiping Li,Xuesong Wang,Yu Wang,Yuanbo Gao,Xiaojun Zheng,Xifen Zhang,Xuxin Li,Xihui Zheng,Xisheng Fan,Guang Zuo,Yanfen She

DOI: https://doi.org/10.2147/jpr.s488343

IF: 2.8319

2024-10-02

Journal of Pain Research

Abstract:Haiping Li, 1, &ast Xuesong Wang, 1, &ast Yu Wang, 1 Yuanbo Gao, 1 Xiaojun Zheng, 1 Xifen Zhang, 1 Xuxin Li, 1 Xihui Zheng, 1 Xisheng Fan, 1, 2 Guang Zuo, 1 Yanfen She 1, 2 1 College of Acupuncture-Moxibustion and Tuina, Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province, People's Republic of China; 2 Hebei International Joint Research Center for Dominant Diseases in Chinese Medicine and Acupuncture, Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Guang Zuo; Yanfen She, Hebei University of Chinese Medicine, No. 3 Xingyuan Road, Shijiazhuang City, Hebei Province, 050200, People's Republic of China, Email ; Background: Acupuncture and related therapies are effective and safe ways to relieve the pain, and improve the health and quality of life in women with endometriosis-related pain. However, it is still unclear which treatment is the most effective. Our study aims to summarize the evidence and determine the most effective and safe method to treat the endometriosis. Methods: We searched PubMed, EMBASE, Cochrane Library, and Web of science, China Biology Medicine, China National Knowledge Infrastructure, Wan fang Data, Chinese Scientific Journal Database and conducted manual searches of relevant papers, summarized randomized clinical trials of acupuncture-related therapies for endometriosis from database inception to 21 April 2024. After independent literature screening and data extraction that pain VAS was selected as the primary outcome measure. The quality evaluation was conducted by Review Manager 5.4. Perform network meta-analysis (NMA) used Stata 15.0 software. Results: Forty-two eligible trials involving six acupuncture-related interventions and 3,635 participants were included in this NMA. Pairwise meta-analyses show that combination therapy was more efficacious than western medicine and Chinese herb medicine for pain VAS scores, serum CA125 level and response rate results. The NMA estimates indicated that: for pain VAS scores, acupuncture (SMD: − 2.33; 95% CI: − 4.37, − 0.29) and combination therapy (SMD: 1.79 95% CI: 1.21, 2.41) were superior to western medicine. For serum CA125 level, acupoint application (SMD: − 11.33 95% CI: − 20.28, − 2.97) and combination therapy (SMD: 6.20; 95% CI: 1.60, 10.75) were associated with better efficacy when considered alongside western medicine. For response rate, combination therapy (SMD: 0.20; 95% CI: 0.14, 0.29) and auricular therapy (SMD: 8.01; 95% CI: 2.08, 45.37) were more efficacious than western medicine. The comprehensive ranking results show that acupoint catgut embedding was the best performing at lowering pain VAS scores, acupoint application was identified as the most effective in reducing serum CA125 level, and auricular therapy was ranked first in improving the response rate. Conclusion: Acupoint catgut embedding, auricular therapy, acupoint application and combination therapy may be the best solutions for the treatment of endometriosis. Additional trials are needed to develop higher-quality evidence and optimal regimens. Keywords: acupuncture, endometriosis, randomized controlled trials, network meta-analysis Endometriosis (EMs) is characterized by the endometrial tissue appears, grows, infiltrates, and bleeds repeatedly in the lining of the uterus and in areas outside of the uterus, subsequently causing pain, joint pain, infertility, and nodules. 1,2 Clinical manifestations include dysmenorrhea, pelvic pain, dyspareunia, and infertility. 3 It affects approximately 6% to 10% of women of childbearing age. 4 Epidemiological studies reveal that women with EMs have a higher risk of developing ovarian and breast cancer, melanoma, asthma, rheumatoid arthritis, and cardiovascular disease. 5 EMs seriously affects women's physical health, mental health and quality of life. 6 Therefore, effective interventions remain critical. Currently, the mainstay of drug therapy for EMs is hormone suppressive drugs. 7 In the context of endometriosis-related pain in patients with no current plans to become pregnant: combined oral contraceptives or progestins are low-cost drugs that should be considered as a first-line medical therapy. 8 Although medication is helpful, a large proportion of women (10.0–43.5%) discontinue drugs due to the presence of side effects, such as uterine bleeding, vomiting, breast discomfort, depression, weight gain, and moodiness. 9–12 As such, non-pharmacolog -Abstract Truncated-

clinical neurology

Low-flow mediated constriction incorporated indices as indicators of cardiovascular risk in smokers.

Wireless wideband SAW sensor - antenna design

Hepatitis B immune globulin (HBIG): efficacy in the interruption of vertical transmission of hepatitis B virus (HBV) carrier state.

Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis Post-hoc analysis of a multicentre, prospective, real-world study

Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties.

Letrozole Combined With Oral Contraceptives Versus Oral Contraceptives Alone In The Treatment Of Endometriosis-Related Pain Symptoms: A Pilot Study

Investigation of the 12-Month Efficacy and Safety of Low-Dose Mifepristone in the Treatment of Painful Adenomyosis

The efficacy and safety of up to 24 weeks of triptorelin therapy following conservative surgery in patients with deep infiltrating endometriosis (DIE): a multicentre, prospective, non-interventional study in China

The Efficacy and Safety of Triptorelin-Therapy Following Conservative Surgery for Deep Infiltrating Endometriosis A Multicenter, Prospective, Non-Interventional Study in China

Beta3-adrenoceptor is involved in the inhibition of small intestinal motility due to restraint stress in rats.

Electronic structure of the neutral manganese acceptor in gallium arsenide.

Does Nomegestrol Acetate Plus 17β-Estradiol Oral Contraceptive Improve Endometriosis-Associated Chronic Pelvic Pain in Women?

A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women

Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

Long acting progestogens versus combined oral contraceptive pill for preventing recurrence of endometriosis related pain: the PRE-EMPT pragmatic, parallel group, open label, randomised controlled trial

Our surgical heritage: the role of the Department of Paediatric Surgery in the development of paediatric surgery in Cape Town, in Africa, and around the world.

Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents

[Effect of reserpine treatment, in doses "depleting" tissue catecholamines, on myocardial sensitivity to procaine amide].

GASTROENTERIC CUTANEOUS FISTULA. TRACT OCCLUSION FOR TREATMENT.

Why do estrogens matter: a systematic review and meta-analysis on use of gnrh antagonists, with or without add-back therapy, for endometriosis-associated pain

Acupuncture and Related Therapies for Endometriosis: A Network Meta-Analysis of Randomized Controlled Trials